LATE RECTAL BLEEDING AND GENITOURINARY MORBIDITY AFTER HIGH DOSE RATE BRACHYTHERAPY COMBINED WITH HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER

この論文にアクセスする

この論文をさがす

著者

    • EBARA Takeshi
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • AKIMOTO Tetsuo
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • KATO Hiroyuki
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • NODA Shin-ei
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • TAMAKI Tomoaki
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • HARADA Kosaku
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • SHIRAI Katsuyuki
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • KAWAMURA Hidemasa
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • SAKURAI Hideyuki
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine
    • NAKANO Takashi
    • Department of Radiation Oncology, Gunma University Graduate School of Medicine

抄録

Purpose: To evaluate late rectal bleeding and genitourinary (GU) morbidity in patients consecutively treated with combined high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). Materials and Methods: Data from 80 patients treated consecutively from October 2000 to May 2004 were analyzed. The median age was 69 years old, median follow-up 31 months, ranging from 17-59 months. All patients received endocrine therapy before radiation therapy. The patients were divided into low-, intermediate- and high-risk groups (4/24/52 patients) according to the risk factors defined by T-classification, PSA and Gleason score. Fractionation schedules for HDR brachytherapy were prospectively changed, and EBRT was fixed with 3 Gy fractions to 51 Gy. The distribution of fractionation was scheduled as follows; 5 Gy×5 times in 14 patients, 7 Gy×3 times in 19 patients, and 9 Gy×2 times in 47 patients. The rectal bleeding was graded using the toxicity criteria of the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer while the genitourinary morbidities were graded using the toxicity criteria of the Common Terminology Criteria for Adverse Events v.3.0.<br>Results: Grade 2 or worse rectal bleeding developed in 9 patients (11.3%) with the 2-year actuarial probability at 11.2%. Grade 2 and 3 rectal bleeding was recognized in 8 and 1 patients, respectively. Grade 3 morbidity developed in the biopsied sites that were performed in the other hospital. No significant difference was observed in any HDR brachytherapy fractionation schedule. Grade 2 or worse GU morbidities were recognized in 30 patients (37.5%), consisting of 29 Grade 2 patients and 1 Grade 3 patient. Twenty-one patients in Grade 2 morbidity had an increase in the frequency of urination or nocturia, and urethral strictures developed in 3 patients. The 3-year actuarial probability of urethral stricture was 6.0%. One patient experienced Grade 3 incontinent. No Grade 4 GU complications was observed.<br>Conclusion: HDR brachytherapy combined with hypofractionated EBRT for localized prostate cancer is feasible considering severity of late rectal and genitourinary morbidity.

収録刊行物

  • The Journal of JASTRO = 日本放射線腫瘍学会誌  

    The Journal of JASTRO = 日本放射線腫瘍学会誌 19(2), 93-97, 2007-06-25 

    Japanese Society for Therapeutic Radiology and Oncology

参考文献:  31件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  1件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021282662
  • NII書誌ID(NCID)
    AN10123988
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    10409564
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ